2′-Hydroxy-4-methylsulfonylchalcone enhances TRAIL-induced apoptosis in prostate cancer cells

Anti-Cancer Drugs

Volumn 26, Issue 1, 2015, Pages 74-84

  Ismail, Bassel ^a   Fagnere, Catherine ^a   Limami, Youness ^a   Ghezali, Lamia ^a   Pouget, Christelle ^a   Fidanzi, Chloë ^a   Ouk, Catherine ^a   Gueye, Rokhaya ^a   Beneytout, Jean Louis ^a   Duroux, Jean Luc ^a   Diab Assaf, Mona ^b   Leger, David Y ^a   Liagre, Bertrand ^a  

^a UNIVERSITY OF LIMOGES   (France)

^b LEBANESE UNIVERSITY   (Lebanon)

Author keywords

apoptosis; chalcone; DR5; PI3K Akt; prostate cancer cells; TRAIL

Indexed keywords

2' HYDROXY 4 METHYLSULFONYLCHALCONE; CASPASE 3; CASPASE 8; CHALCONE DERIVATIVE; CYCLOOXYGENASE 2; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DNA FRAGMENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROCASPASE 3; PROTEIN BCL 2; PROTEIN KINASE B; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; 2'-HYDROXY-4-METHYLSULFONYLCHALCONE; 4'-CHLORO-2'-HYDROXY-4-METHYLSULFONYLCHALCONE; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; SULFONE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; DNA CONTENT; DNA FRAGMENTATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IC50; PHASE CONTRAST MICROSCOPY; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; UPREGULATION; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CHALCONES; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; MALE; NF-KAPPA B; PROSTATIC NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; SULFONES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION FACTOR AP-1;

EID: 84916598679     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000163     Document Type: Article

References (68)

1. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3:673-682.
2. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271:12687-12690.
3. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5:157-163.
4. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104:155-162.
5. Voelkel-Johnson C. TRAIL-mediated signaling in prostate, bladder and renal cancer. Nat Rev Urol 2011; 8:417-427.
6. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003; 10:66-75.
7. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2:420-430.
8. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005; 12:228-237.
9. Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS, et al. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 1998; 58:1593-1598.
10. Aza-Blanc P, Cooper CL, Wagner K, Batalov S, Deveraux QL, Cooke MP. Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. Mol Cell 2003; 12:627-637.
11. Kandasamy K, Srivastava RK. Role of the phosphatidylinositol 3′-kinase/ PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res 2002; 62:4929-4937.
12. Chawla-Sarkar M, Bauer JA, Lupica JA, Morrison BH, Tang Z, Oates RK, et al. Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL. J Biol Chem 2003; 278:39461-39469.
13. Jani TS, DeVecchio J, Mazumdar T, Agyeman A, Houghton JA. Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem 2010; 285:19162-19172.
14. Jung EM, Park JW, Choi KS, Park JW, Lee HI, Lee KS, Kwon TK. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through CHOP-independent DR5 upregulation. Carcinogenesis 2006; 27:2008-2017.
15. Rachner TD, Singh SK, Schoppet M, Benad P, Bornhäuser M, Ellenrieder V, et al . Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett 2010; 287:109-116.
16. Zhu H, Liu XW, Ding WJ, Xu DQ, Zhao YC, Lu W, et al. Up-regulation of death receptor 4 and 5 by celastrol enhances the anti-cancer activity of TRAIL/Apo-2L. Cancer Lett 2010; 297:155-164.
17. Jacquemin G, Shirley S, Micheau O. Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells? Cell Mol Life Sci 2010; 67:3115-3130.
18. Jin CY, Park C, Kim GY, Lee SJ, Kim WJ, Choi YH. Genistein enhances TRAIL-induced apoptosis through inhibition of p38 MAPK signaling in human hepatocellular carcinoma Hep3B cells. Chem Biol Interact 2009; 180:143-150.
19. Um HJ, Oh JH, Kim YN, Choi YH, Kim SH, Park JW, Kwon TK. The coffee diterpene kahweol sensitizes TRAIL-induced apoptosis in renal carcinoma Caki cells through down-regulation of Bcl-2 and c-FLIP. Chem Biol Interact 2010; 186:36-42.
20. Szliszka E, Krol W. The role of dietary polyphenols in tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis for cancer chemoprevention. Eur J Cancer Prev 2011; 20:63-69.
21. Jin CY, Park C, Moon SK, Kim GY, Kwon TK, Lee SJ, et al. Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage. Anticancer Drugs 2009; 20:713-722.
22. Cárdenas MG, Blank VC, Marder MN, Roguin LP. 2′-Nitroflavone induces apoptosis and modulates mitogen-activated protein kinase pathways in human leukaemia cells. Anticancer Drugs 2012; 23:815-826.
23. Lee DH, Lee CS, Kim DW, Ae JE, Lee TH. Digitoxin sensitizes glioma cells to TRAIL-mediated apoptosis by upregulation of death receptor 5 and downregulation of survivin. Anticancer Drugs 2014; 25:44-52.
24. Kostanecki SV, Tambor J. Ueber die sechs isomeren monooxybenzalacetophenone (monooxychalkone). Ber Dtsch Chem Ges 1899; 32:1921-1926.
25. Alcaraz MJ, Vicente AM, Araico A, Dominguez JN, Terencio MC, Ferrándiz ML. Role of nuclear factor-kappaB and heme oxygenase-1 in the mechanism of action of an anti-inflammatory chalcone derivative in RAW 264.7 cells. Br J Pharmacol 2004; 142:1191-1199.
26. Dominguez JN, León C, Rodrigues J, Gamboa de Domínguez N, Gut J, Rosenthal PJ. Synthesis and evaluation of new antimalarial phenylurenyl chalcone derivatives. J Med Chem 2005; 48:3654-3658.
27. Sabzevari O, Galati G, Moridani MY, Siraki A, O'Brien PJ. Molecular cytotoxic mechanisms of anticancer hydroxychalcones. Chem Biol Interact 2004; 148:57-67.
28. Kim TH, Seo WD, Ryu HW, Seo HR, Jin YB, Lee M, et al. Anti-tumor effects by a synthetic chalcone compound is mediated by c-Myc-mediated reactive oxygen species production. Chem Biol Interact 2010; 188:111-118.
29. Kim SY, Lee IS, Moon A. 2-Hydroxychalcone and xanthohumol inhibit invasion of triple negative breast cancer cells. Chem Biol Interact 2013; 203:565-572.
30. Yun JM, Kweon MH, Kwon H, Hwang JK, Mukhtar H. Induction of apoptosis and cell cycle arrest by a chalcone panduratin A isolated from Kaempferia pandurata in androgen-independent human prostate cancer cells PC3 and DU145. Carcinogenesis 2006; 27:1454-1464.
31. Szliszka E, Czuba ZP, Mazur B, Sedek L, Paradysz A, Krol W. Chalcones enhance TRAIL-induced apoptosis in prostate cancer cells. Int J Mol Sci 2009; 11:1-13.
32. Szliszka E, Czuba ZP, Mazur B, Paradysz A, Krol W. Chalcones and dihydrochalcones augment TRAIL-mediated apoptosis in prostate cancer cells. Molecules 2010; 15:5336-5353.
33. Tang Y, Li X, Liu Z, Simoneau AR, Xie J, Zi X. Flavokawain B, a kava chalcone, induces apoptosis via up-regulation of death-receptor 5 and Bim expression in androgen receptor negative, hormonal refractory prostate cancer cell lines and reduces tumor growth. Int J Cancer 2010; 127:1758-1768.
34. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006; 71:1397-1421.
35. Zhang EH, Wang RF, Guo SZ, Liu B. An update on antitumor activity of naturally occurring chalcones. Evid Based Complement Alternat Med 2013; 2013:815621.
36. Hu W, Kavanagh JJ. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 2003; 4:721-729.
37. Shen KH, Chang JK, Hsu YL, Kuo PL. Chalcone arrests cell cycle progression and induces apoptosis through induction of mitochondrial pathway and inhibition of nuclear factor kappa B signalling in human bladder cancer cells. Basic Clin Pharmacol Toxicol 2007; 101:254-261.
38. Ismail B, Ghezali L, Gueye R, Limami Y, Pouget C, Leger DY, et al. Novel methylsulfonyl chalcones as potential antiproliferative drugs for human prostate cancer: involvement of the intrinsic pathway of apoptosis. Int J Oncol 2013; 43:1160-1168.
39. Lepage C, Léger DY, Bertrand J, Martin F, Beneytout JL, Liagre B. Diosgenin induces death receptor-5 through activation of p38 pathway and promotes TRAIL-induced apoptosis in colon cancer cells. Cancer Lett 2011; 301:193-202.
40. Bertrand J, Liagre B, Ghezali L, Beneytout JL, Leger DY. Cyclooxygenase-2 positively regulates Akt signalling and enhances survival of erythroleukemia cells exposed to anticancer agents. Apoptosis 2013; 18:836-850.
41. Corbiere C, Liagre B, Terro F, Beneytout JL. Induction of antiproliferative effect by diosgenin through activation of p53, release of apoptosis-inducing factor (AIF) and modulation of caspase-3 activity in different human cancer cells. Cell Res 2004; 14:188-196.
42. Ghezali L, Leger DY, Limami Y, Cook-Moreau J, Beneytout JL, Liagre B. Cyclopamine and jervine induce COX-2 overexpression in human erythroleukemia cells but only cyclopamine has a pro-apoptotic effect. Exp Cell Res 2013; 319:1043-1053.
43. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91:231-241.
44. Kirschenbaum A, Liu X, Yao S, Levine AC. The role of cyclooxygenase-2 in prostate cancer. Urology 2001; 58:127-131.
45. Lee KS, Lee HJ, Ahn KS, Kim SH, Nam D, Kim DK, et al. Cyclooxygenase-2/ prostaglandin E2 pathway mediates icariside II induced apoptosis in human PC-3 prostate cancer cells. Cancer Lett 2009; 280:93-100.
46. Liu YQ, Hu XY, Lu T, Cheng YN, Young CY, Yuan HQ, Lou HX. Retigeric acid B exhibits antitumor activity through suppression of nuclear factor-κB signaling in prostate cancer cells in vitro and in vivo. PLoS One 2012; 7:e38000.
47. Zhu B, Li X, Zhang Y, Ye C, Wang Y, Cai S, et al . Cross-talk of alpha tocopherol-associated protein and JNK controls the oxidative stress-induced apoptosis in prostate cancer cells. Int J Cancer 2013; 132:2270-2282.
48. Bernardino J, Bourgeois CA, Muleris M, Dutrillaux AM, Malfoy B, Dutrillaux B. Characterization of chromosome changes in two human prostatic carcinoma cell lines (PC-3 and DU145) using chromosome painting and comparative genomic hybridization. Cancer Genet Cytogenet 1997; 96:123-128.
49. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005; 5:773-785.
50. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470:214-220.
51. Ray S, Shyam S, Fraizer GC, Almasan A. S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells. Mol Cancer Ther 2007; 6:1368-1378.
52. Kim HB, Kim MJ, Kim DY, Lee JW, Bae JH, Kim DW, et al. High susceptibility of metastatic cells derived from human prostate and colon cancer cells to TRAIL and sensitization of TRAIL-insensitive primary cells to TRAIL by 4,5-dimethoxy-2-nitrobenzaldehyde. Mol Cancer 2011; 10:46.
53. Catz SD, Johnson JL. BCL-2 in prostate cancer: a minireview. Apoptosis 2003; 8:29-37.
54. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, et al . Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 2001; 20:6073-6083.
55. Xu J, Zhou JY, Wei WZ, Wu GS. Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PLoS One 2010; 5:e10226.
56. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001; 142:4795-4805.
57. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001; 98:10983-10985.
58. Peuhu E, Rivero-Müller A, Stykki H, Torvaldson E, Holmbom T, Eklund P, et al. Inhibition of Akt signaling by the lignan matairesinol sensitizes prostate cancer cells to TRAIL-induced apoptosis. Oncogene 2010; 29:898-908.
59. Madrid LV, Mayo MW, Reuther JY, Baldwin AS Jr. Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem 2001; 276:18934-18940.
60. Ahn KS, Sethi G, Aggarwal BB. Nuclear factor-kappa B: from clone to clinic. Curr Mol Med 2007; 7:619-637.
61. Ameyar M, Wisniewska M, Weitzman JB. A role for AP-1 in apoptosis: the case for and against. Biochimie 2003; 85:747-752.
62. Zhang X, Zhang L, Yang H, Huang X, Otu H, Libermann TA, et al. c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res 2007; 67:9425-9434.
63. Yang P, Cartwright CA, Li J, Wen S, Prokhorova IN, Shureiqi I, et al. Arachidonic acid metabolism in human prostate cancer. Int J Oncol 2012; 41:1495-1503.
64. Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010; 29:781-788.
65. Patsos HA, Greenhough A, Hicks DJ, Al Kharusi M, Collard TJ, Lane JD, et al. The endogenous cannabinoid, anandamide, induces COX-2-dependent cell death in apoptosis-resistant colon cancer cells. Int J Oncol 2010; 37:187-193.
66. Limami Y, Pinon A, Leger DY, Mousseau Y, Cook-Moreau J, Beneytout JL, et al. HT-29 colorectal cancer cells undergoing apoptosis overexpress COX-2 to delay ursolic acid-induced cell death. Biochimie 2011; 93:749-757.
67. Limami Y, Pinon A, Leger DY, Pinault E, Delage C, Beneytout JL, et al. The P2Y2/Src/p38/COX-2 pathway is involved in the resistance to ursolic acidinduced apoptosis in colorectal and prostate cancer cells. Biochimie 2012; 94:1754-1763.
68. Giri DK, Aggarwal BB. Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J Biol Chem 1998; 273:14008-14014.